Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 4, 2004, Pages 1181-1189

  Mason, Kathy A ^a   Hunter, Nancy R ^a   Raju, Uma ^a   Ariga, Hisanori ^a   Husain, Amir ^a   Valdecanas, David ^a   Neal, Robert ^a   Ang, Kian K ^b   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Antitumor and antimetastatic activity; Flavopiridol; Murine tumors; Radioresponse

Indexed keywords

CELL CULTURE; ENZYMES; MATHEMATICAL MODELS; RADIOTHERAPY; TUMORS;

RADIOENHACEMENT; THERAPEUTIC RATIO;

ONCOLOGY;

FLAVOPIRIDOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; LYMPHOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DOSE FRACTIONATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; JEJUNUM; LUNG NEOPLASMS; MICE; MICE, INBRED C3H; OVARIAN NEOPLASMS; PIPERIDINES; RADIATION-SENSITIZING AGENTS;

EID: 3042661952     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.03.003     Document Type: Article

References (31)

1. MacLachlan T.K., Sang N., Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors Implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr. 5:1995;127-156
2. Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst. 89:1997;341-343
3. Zafonte B.T., Hulit J., Amanatullah D.F., et al. Cell-cycle dysregulation in breast cancer Breast cancer therapies targeting the cell cycle. Front Biosci. 5:2000;D938-D961
4. Milas L., Fan Z., Mason K.A., et al. Role of epidermal growth factor receptor (EGFR) and its inhibition in radiotherapy. Neider C., Milas L., Ang K.K. Modification of radiation response. 2002;189-201 Springer-Verlag, Heidelberg, Germany
5. Monga M., Sausville E.A. Developmental therapeutics program at the NCI Molecular target and drug discovery process. Leukemia. 16:2002;520-526
6. Senderowicz A.M., Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 92:2000;376-387
7. Kaur G., Stetler-Stevenson M., Sebers S., et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 84:1992;1736-1740
8. Sedlacek H.H. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol. 38:2001;139-170
9. Carlson B., Lahusen T., Singh S., et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59:1999;4634-4641
10. Melillo G., Sausville E.A., Cloud K., et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 59:1999;5433-5437
11. Rapella A., Negrioli A., Melillo G., et al. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int J Cancer. 99:2002;658-664
12. Bible K.C., Kaufmann S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents the importance of sequence of administration. Cancer Res. 57:1997;3375-3380
13. Motwani M., Rizzo C., Sirotnak F., et al. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther. 2:2003;549-555
14. Motwani M., Delohery T.M., Schwartz G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 5:1999;1876-1883
15. Motwani M., Jung C., Sirotnak F.M., et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res. 7:2001;4209-4219
16. Schwartz G.K., Farsi K., Maslak P., et al. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res. 3:1997;1467-1472
17. Wu K., Wang C., D'Amico M., et al. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells Association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther. 1:2002;695-706
18. Chien M., Astumian M., Liebowitz D., et al. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol. 44:1999;81-87
19. Russell JS, Manspeaker KA, Ridnour LA, et al. Radiosensitization of human tumor cell lines by flavopiridol. Proc AACR 2002;43:649
20. Raju U., Nakata E., Mason K.A., et al. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res. 63:2003;3263-3267
21. Milas L., Hunter N., Mason K., et al. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res. 34:1974;61-71
22. Withers H.R., Elkind M.M. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med. 17:1970;261-267
23. Volpe J.P., Hunter N., Basic I., et al. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin Exp Metastasis. 3:1985;281-294
24. Mason KA, Raju U, Hunter N, et al. Flavopiridol enhances tumor response to radiotherapy [Abstract]. In: Steven M. Grunberg M, editor. Thirty-Ninth Annual Meeting of the American Society of Clinical Oncology. Vol. 22. Chicago, IL: 2003. p. 865
25. Teicher B.A., Holden S.A., Dupuis N.P., et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat. 36:1995;227-236
26. Gorski D.H., Mauceri H.J., Salloum R.M., et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 58:1998;5686-5689
27. Perrotte P., Matsumoto T., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 5:1999;257-265
28. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 6:2000;701-708
29. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:1999;3374-3378
30. Haimovitz-Friedman A., Vlodavsky I., Chaudhuri A., et al. Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res. 51:1991;2552-2558
31. Mazure N.M., Chen E.Y., Laderoute K.R., et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 90:1997;3322-3331